Get the weekly note
ETFIQetfiq.com · independent ETF data

Data as of .

LFSC vs TNXT: which is really different?

LFSC and TNXT hold 3% of their weight in the same names.

F/m Emerald Life Sciences Innovation ETF and T. Rowe Price Innovation Leaders ETF.

0.0%LFSC in the S&P 500
64.3%TNXT in the S&P 500
+53.0%LFSC total return, 1 year
+14.5%TNXT total return, 1 year

ETFIQ Off-Index Score: LFSC scores higher

How much of it is not the index it is sold as an alternative to?

LFSC 91.8TNXT 0.70.1, the lowest in this set91.8, the highest

A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed

LFSC100% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
0%100%0% of its weight in S&P 500 companiesof its weight outside the S&P 500active share 100% · top ten 55% of the fund · 39 holdings filed May 31, 2026 · Nasdaq-100: 1% in0%100%0% of its weight in S&P 500 companiesof its weight outside the S&P 500active share 100% · top ten 55% of the fund
TNXT36% of its weight is outside the S&P 500 · 6 months to Sep 18, 2026
64%36%of its weight in S&P 500 companiesof its weight outside the S&P 500active share 52% · top ten 32% of the fund · 272 holdings filed Jun 30, 2026 · Nasdaq-100: 47% in64%36%in the S&P 500outsideactive share 52% · top ten 32% of the fund

3% of the two portfolios are the same securities at the same weight.

What they hold in common

By the books each fund has filed, LFSC and TNXT hold 3% of their money in the same securities at the same weight.

Positions LFSC and TNXT both hold, largest shared weight first
HoldingLFSCTNXT
Guardant Health Inc5.51%0.70%
Spyre Therapeutics Inc6.41%0.33%
Twist Bioscience Corp1.14%0.27%
Billiontoone Inc2.73%0.25%
Dianthus Therapeutics Inc3.09%0.21%
Insmed Inc0.61%0.18%
Cytokinetics Inc3.16%0.14%
United Therapeutics Corp4.15%0.14%
Axsome Therapeutics Inc2.84%0.12%
Mirum Pharmaceuticals Inc4.92%0.11%
Palvella Therapeutics Inc1.95%0.10%
Viridian Therapeutics Inc2.23%0.10%
Only in each
Only in LFSCOnly in TNXT
Travere Therapeutics Inc 7.66%NVIDIA CORP 7.23%
Cogent Biosciences Inc 7.52%APPLE INC 4.61%
LivaNova PLC 7.11%AMAZON.COM INC 3.02%
Corcept Therapeutics Inc 4.79%BROADCOM INC 2.76%
VeraDermics Inc 3.42%MICROSOFT CORP 2.67%
Savara Inc 3.22%ALPHABET INC CL A 2.57%
Nektar Therapeutics 3.14%ADVANCED MICRO DEVICES 2.53%
Trevi Therapeutics Inc 3.12%ALPHABET INC CL C 2.28%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.

Performance, window by window

LFSC and TNXT over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ.
WindowTotal returnvs the S&P 500vs the Nasdaq-100
LFSCTNXTLFSCTNXTLFSCTNXT
3 months+8.7%+3.8%+6.5 pts+1.6 pts+11.2 pts+6.3 pts
6 months+36.0%+27.4%+17.9 pts+9.3 pts+11.7 pts+3.1 pts
1 year+53.0%not published+36.5 ptsnot published+31.3 ptsnot published
Since launch+81.3%+14.5%+44.3 pts+3.9 pts+30.9 pts−0.4 pts
Open the live comparison on ETFIQ
LFSC and TNXT on the same fields, as of Sep 18, 2026. Source: ETFIQ.
LFSC
F/m Emerald Life Sciences Innovation ETF
Holds 39 stocks in broad innovation and megatrends, 0% of its weight in S&P 500 companies
TNXT
T. Rowe Price Innovation Leaders ETF
Holds 272 stocks in broad innovation and megatrends, 64% of its weight in S&P 500 companies
IssuerF/mT. Rowe Price
ThemeBroad innovation and megatrendsBroad innovation and megatrends
In the S&P 5000.0%64.3%
Active share vs the S&P 500100.0%51.6%
In the Nasdaq-1000.6%46.9%
Holdings39272
Top ten, share of the fund54.7%31.8%
Expense ratio0.54%0.49%
Fee for the differing part0.54%0.95%
Total return, 1 year+53.0%+14.5% (since launch on Jan 29, 2026)
vs the S&P 500+36.5 pts+3.9 pts
vs the Nasdaq-100+31.3 pts−0.4 pts
Below its high−6.8%−1.4%
Net assets$105m$18m

LFSC in plain words

By weight, 0% of LFSC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 55% of the fund across 39 positions, as filed for May 31, 2026. Over the year to Sep 18, 2026 the fund returned +53.0% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 36.5 pts. It sits 6.8% below its all-time high of Aug 19, 2026.

TNXT in plain words

By weight, 64% of TNXT's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 52%. The top ten holdings are 32% of the fund across 272 positions, as filed for Jun 30, 2026. Since it launched on Jan 29, 2026 the fund returned +14.5% with distributions reinvested against +10.6% for the S&P 500, so a holder was ahead by 3.9 pts.

Questions people ask

Do LFSC and TNXT hold the same stocks?
By their latest filings, 3% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, LFSC or TNXT?
LFSC has 0% of its weight in S&P 500 names and TNXT has 64%, so LFSC differs more from the index.
Which is cheaper, LFSC or TNXT?
LFSC charges 0.54% a year and TNXT charges 0.49%, so TNXT is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

LFSC against TNXT, ETFIQ, data as of Sep 18, 2026. Every figure is calculated from a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, LFSC against TNXT, data as of Sep 18, 2026. https://etfiq.com/compare/themes/lfsc-vs-tnxt Free to use with attribution; the underlying files are at Open data.

How every figure is computed · Standards and sources